People
Aprea Therapeutics completes EUR50m Series C financing round
4 December 2018 -

Aprea Therapeutics, a biopharmaceutical company engaged in the discovery and development of anticancer compounds that reactivate the tumour suppressor protein, p53, has completed a EUR50m Series C financing round, it was reported yesterday.

Redmile Group has headed the Series C financing round, with participation by new investor Rock Springs Capital and existing investors 5AM Ventures, Versant Ventures, HealthCap, Sectoral Asset Management and Karolinska Development. A representative from Redmile Group will also be appointed as director to the Aprea Therapeutics board of directors.

Proceeds from the financing will be utilised to advance the clinical development of APR-246, a first-in-class anticancer agent that reactivates mutated p53 tumour suppressor protein.

Login
Username:

Password: